Implementing the generalized pustular psoriasis (GPP) Charter
Read more about the projects are implementing the generalized pustular psoriasis (GPP) Charter
Search
clinical_collaboration_with_Mirati
Boehringer Ingelheim and Mirati are teaming up in a clinical collaboration to evaluate the combination of the SOS1::pan-KRAS and the selective G12C inhibitor.
10 tips cat friendly veterinary clinics
Here are 10 simple steps you can take to make feline patients feel at ease at your practice.
From social worker to joining the pharmaceutical industry
Patient centricity: How Miyuki Ono contributes to our diverse workforce with her experience as a social worker and helps patients in Japan
emperor-preserved-heart-failure-toplineresults
Positive, top-line results announced from the EMPEROR-Preserved Phase III trial in adults with heart failure with preserved ejection fraction
The Goals to Improve Living with GPP
An article that describes the current goals to improve the lives of those living with generalized pustular psoriasis
Human Health Partnering
Human Health Partnering
How do I treat mild to moderate renal impairment with Pradaxa®
.
Artrial Fibrillation
Artrial Fibrillation
preserved-heart-failure-treatment-approval-europe
preserved-heart-failure-treatment-approval-europe
Immunology Respiratory Research
Find out more about our research and development in Immunology & Respiratory diseases
Behind the Lab
Delve behind the lab to see how our Retinal Health scientists are spearheading research into novel therapeutics to treat retinopathies.
BI_X_Shanghai
Boehringer Ingelheim opens a second branch of its digital lab in Shanghai
Our Responsibility
Human Health Our Responsibility
Data Science
Revolutionizing research and development with data driven insights
License to develop new fibro-inflammatory disease treatments
License to develop new fibro-inflammatory disease treatments
Improving Access to Stroke Care
Angels Initiative named Best Practice example by the Access to Medicine Index
CHMP recommends conditional approval for first GPP treatment
CHMP recommends conditional marketing authorization for novel IL-36 receptor monoclonal antibody, spesolimab, as first treatment for generalized pustular psoriasis flares
Survodutide Phase III study weight loss
Boehringer Ingelheim to advance survodutide into three global Phase III studies in obesity
Partnering-with-google-in-quantum-computing
New cooperation with Google explores the potentials of quantum computing for pharma R&D.
Clinical Studies
Clinical Studies
European Commission approves SPEVIGO® (spesolimab) for generalized pustular psoriasis flares
European Commission grants marketing authorization for spesolimab, the first specific treatment option for generalized pustular psoriasis flares in adults
Fostering Science
Fostering Science
Positivity... just a paw away
Data released by Boehringer Ingelheim shows the 96% of dog owners and 91% of cat owners claim their pet has a positive impact on their daily lives.
university-of-medical-excellence-harvard
A program designed by Harvard Medical School Executive Education with the goal of accelerating clinical development and medical affairs